Shionogi lands $375M from HHS to develop preventive drug for Covid-19
After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to develop …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
